… therapy with tezacaftor and ivacaftor in patients 12 years of age or older who had cystic fibrosis
and … either 100 mg of tezacaftor once daily and 150 mg of ivacaftor twice daily or matched …

… Our findings show the safety and efficacy of tezacaftor–ivacaftor treatment in patients who
had cystic fibrosis and were heterozygous for the Phe508del CFTR mutation and a second …

… cystic fibrosis, 20 and elexacaftor–tezacaftor–ivacaftor resulted in sustained improvements
in this end point. Pulmonary … –tezacaftor–ivacaftor resulted in a lower rate of pulmonary …

… –tezacaftor–ivacaftor … tezacaftor–ivacaftor doses in triple combination were then evaluated
in randomized, controlled, double-blind, multicenter trials involving patients with cystic fibrosis …

… /tezacaftor/ivacaftor (ETI) is a modulator drug shown to provide substantial health benefits
and improved cystic fibrosis … majority of people with cystic fibrosis and represents a milestone …

… dual therapy with tezacaftor-ivacaftor. Quality of life was evaluated using the Cystic Fibrosis
… of 17.4 points with elexacaftor-tezacaftor-ivacaftor versus tezacaftor-ivacaftor. This met the …

… We show that in the first clinical trial evaluating tezacaftor combined with ivacaftor, the …
Cystic fibrosis (CF) affects an estimated 70,000 children and adults worldwide and is the …

… (a new corrector)-Tezacaftor-Ivacaftor (Trikafta or Kaftrio) leads … of in-vitro responsiveness
to Ivacaftor/Tezacaftor [6]. This triple … of the Elexacaftor/Tezacaftor/Ivacaftor combination in the …

… a CFTR modulator versus those treated with another CFTR modulator (ivacaftor,
lumacaftor–ivacaftor, or tezacaftor–ivacaftor) at the time of initiation of elexacaftor–tezacaftor–ivacaftor. …

… of the potentiator ivacaftor (VX-770) and the correctors lumacaftor (VX-809), tezacaftor (VX-…
of CFTR modulators composed of elexacaftor, tezacaftor, and ivacaftor (ETI) represents a life-…